FDA 483 - Dr. Reddy's Laboratories Ltd. - October 30, 2018

During an inspection conducted from October 22-30, 2018, Dr. Reddy's Laboratories Ltd., a drug product manufacturer in Visakhapatnam, India, received an FDA Form 483 citing eight significant observations related to Current Good Manufacturing Practices (cGMP). Key violations included a lack of adequate written procedures and controls for production, specifically concerning critical sealing defects in injectable drug products. For instance, a Docetaxel Injection lot was recalled due to seal and stopper failures, with critical sealing parameters unvalidated, a recurring issue from previous inspections. The firm also failed to conduct comprehensive investigations for out-of-specification results, releasing affected batches with known equipment defects, such as a tablet batch with low assay values due to a defective machine. Further issues involved inadequate aseptic process simulations (media fills), which did not accurately represent routine operations or critical interventions, and deficient environmental monitoring in sterile processing areas. Recurring aborted HPLC sequence events were not thoroughly reviewed with effective corrective actions. Significant deficiencies were also noted in employee training programs, leading to insufficient knowledge and numerous atypical events, and batch records lacked complete identification of personnel performing critical steps. Finally, the company failed to submit a Field Alert Report in a timely manner regarding a critical sealing defect complaint, distributing affected product before reporting it. To address these findings, Dr. Reddy's Laboratories Ltd. must establish robust written procedures, validate critical processes, expand investigation scopes, ensure accurate aseptic process simulations, improve environmental controls, implement effective corrective and preventive actions for repeat issues, enhance employee training, maintain complete batch records, and adhere to regulatory reporting timelines for product quality issues.